The major challenge of this promising technology has so far been the transport of RNAi molecules into the target cell. Mirus’ delivery platform provides an innovative way of effectively getting RNAi therapeutics to specific disease targets. RNAi – a natural mechanism that the body uses to ‘silence’ certain genes – represents a potential whole new class of therapeutics for difficult to treat diseases.
Roche’s mission is to find novel solutions for patients who suffer from difficult to treat diseases. RNAi therapeutics provides the capabilities to target complex diseases such as cancer, respiratory or metabolic disorders.
Lee E. Babiss, Global Head of Roche Pharma Research said, The pioneering work in RNAi delivery by the scientists at Mirus, together with our Centre of Excellence for RNAi research in Kulmbach, puts Roche at the forefront of bringing this whole new class of treatment to patients who suffer from difficult to treat diseases. Our global research team has made great strides in advancing RNAi therapeutics, and with our new colleagues in Madison we will now bolster those efforts. The technology brought by Mirus, together with additional technologies, will bring us closer to creating fully enabled RNAi therapeutics.
Russell R. Smestad, President of Mirus said, The expertise, resources and commitment that Roche brings to the RNAi field make Roche an ideal partner for Mirus. ogether we will be able to greatly accelerate the progress we would have accomplished independently.